The regulation of biologic products derived from bioengineered plants
| Autor: | Kathryn E. Stein, Keith O Webber |
|---|---|
| Rok vydání: | 2001 |
| Předmět: |
Biological Products
Commercial scale United States Food and Drug Administration business.industry DNA Recombinant Legislation as Topic Biomedical Engineering Bioengineering Genetically modified crops Biology Plants Genetically Modified United States Biotechnology Biologic Products Biosafety Seeds Animals Humans Plant system Genetic Engineering United States Department of Agriculture business Glycoproteins |
| Zdroj: | Current Opinion in Biotechnology. 12:308-311 |
| ISSN: | 0958-1669 |
| DOI: | 10.1016/s0958-1669(00)00217-2 |
| Popis: | Recently, there has been a large increase in the number and types of biological products — from therapeutic antibodies to vaccines for the prevention of infectious diseases — that are produced in bioengineered plant systems. We anticipate that this technology will be used increasingly on a commercial scale for the manufacture of human and animal products. These production systems have the capacity to produce very large quantities of products at lower costs and with reduced risks compared with mammalian systems. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect